Zivo Bioscience, Inc.
17.00+2.46 (+16.9%)
Oct 28, 4:00:00 PM EDT · OTC Markets OTCQB · ZIVO · USD
Key Stats
Market Cap
64.89MP/E (TTM)
-Basic EPS (TTM)
-2.89Dividend Yield
0%Recent Filings
8-K
Algae tech breakthroughs validated
Zivo Bioscience issued a CEO letter on September 10, 2025, touting breakthrough validation of its algae technology, showing nearly double superoxide dismutase activity versus competitors, alongside rich antioxidants like beta-carotene and lutein. This positions the company for growth in human nutrition via active nutraceutical talks and animal health through proven immune boosts in poultry trials that delay avian influenza spread. Yet liquidity challenges persist amid capital-raising efforts. Ongoing studies could reshape markets.
8-K
Board Resignation Hits Zivo
Zivo Bioscience's board saw a sudden shift on August 12, 2025, when Nola Masterson resigned immediately as director, chair of the Nominating and Governance Committee, and member of Audit and Compensation—yet without any disputes over operations or policies. No replacement has been named, leaving the seat open amid the biotech's ongoing challenges. Smooth transition, for now.
10-Q
Q2 FY2025 results
Zivo Bioscience posted Q2 revenue of $53,400 from algal biomass sales, up from zero a year ago, yielding a $17,922 gross margin—yet operating losses narrowed to $1.6 million from $8.2 million, thanks to slashed equity compensation in G&A and R&D. For the half-year, revenue climbed 49.5% y/y to $53,400 (derived), but net loss widened to $5.9 million from $9.5 million, driven by $2.7 million in exchange agreement expenses for settling R&D participation rights via 146,660 shares. Cash dwindled to $9,823 after $1.9 million operating burn, offset by $374,000 in financing; total debt sits at $477,391 including a $292,919 insurance loan at 7.85%, with $300,742 in lease liabilities through 2030. Losses persist. Funding remains tight.
8-K
Convertible debt offering launched
Zivo Bioscience launched a $2 million convertible debt offering on July 8, 2025, issuing an initial $250,000 bridge note at 10% interest with a warrant for 1,793 common shares. Notes convert automatically into stock at a discount upon a $5 million qualified financing or two-year maturity, or upon change of control if elected. This bridge funding bolsters liquidity while diluting equity on conversion. Warrants add sweetener for investors.
8-K
Shareholders back board, auditors
Zivo Bioscience shareholders convened their annual meeting on June 9, 2025, electing John B. Payne and Alison A. Cornell as Class III directors for three-year terms, while ratifying BDO USA as auditors for the fiscal year and approving executive compensation on an advisory basis. With 66.11% of shares represented, support exceeded 97% for auditors and 96% for pay, signaling strong governance alignment. Directors now steer through biotech uncertainties.
IPO
Employees
Sector
Industry
ADPT
Adaptive Biotechnologies Corpor
16.90-0.22
BDPT
Bioadaptives, Inc.
0.03+0.00
BIOE
Bio Essence Corp.
0.07+0.00
BIVI
BioVie Inc.
1.86-0.03
IBO
Impact BioMedical, Inc.
0.58-0.01
LEXX
Lexaria Bioscience Corp.
0.95-0.05
NAGE
Niagen Bioscience, Inc.
7.27-0.33
PETV
PetVivo Holdings Inc.
1.49-0.01
VIVS
VivoSim Labs, Inc.
2.28-0.01
ZEOX
Zeo ScientifiX Inc.
1.97+0.09